April 2026 in “Frontiers in Immunology” This study concluded that the CXCL12–CXCR4 signaling pathway significantly contributes to hair loss in androgenetic alopecia and alopecia areata by promoting inflammation and fibrosis, whereas inhibiting this pathway can restore hair growth and follicle health.
May 2026 in “Theranostics” This study found that the DKK3-CKAP4 signaling axis is involved in fibroimmune remodeling in androgenetic alopecia and that targeting this pathway may restore a regenerative hair follicle environment, offering a potential therapeutic strategy to counteract hair follicle miniaturization.
July 2025 in “International Journal of Molecular Sciences” This study found that blocking the chemokine CXCL12 in a testosterone-induced mouse model of androgenetic alopecia restored hair regeneration and reduced fibrosis and immune alterations.
August 2026 in “The FASEB Journal” This study identified two key epigenetic-related genes, HR and SMYD4, which may act as potential biomarkers in keloid disease, suggesting new therapeutic avenues for further research.
May 2026 in “Frontiers in Cell and Developmental Biology” In this study, researchers suggest that hair follicle miniaturization in conditions like androgenetic alopecia may result from impaired conversion of quiescent stem cells to progenitor cells, influenced by the follicular niche, its collagen network, and various mechanical constraints.